Propanc Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PPCB Nasdaq 2836 www.propanc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Propanc Biopharma, Inc.

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal - Jul 21st, 2026 6:30 am
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd - Jul 7th, 2026 6:30 am
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program - Jul 2nd, 2026 6:30 am
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study - Jun 16th, 2026 6:45 am
PPCB Stock Surges Over 200% Just Days After Implementing Reverse Share Split – What’s Driving Today’s Smashing Rally? - Jun 11th, 2026 10:37 am
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program - Jun 11th, 2026 6:30 am
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain - Jun 2nd, 2026 3:30 am
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade - May 20th, 2026 6:45 am
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients - May 19th, 2026 6:45 am
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results - May 15th, 2026 6:45 am
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans - May 13th, 2026 8:00 pm
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain - Mar 24th, 2026 6:45 am
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy - Mar 12th, 2026 6:45 am
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study - Mar 10th, 2026 6:45 am
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models - Mar 3rd, 2026 6:45 am
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results - Feb 18th, 2026 6:45 am
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market - Feb 5th, 2026 6:45 am
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations - Jan 27th, 2026 6:45 am
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - Jan 20th, 2026 6:45 am
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer - Jan 15th, 2026 6:45 am